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ABSTRACT The well-characterized association between HLA-B*27:05 and protection
against HIV disease progression has been linked to immunodominant HLA-B*27:05-
restricted CD8 T-cell responses toward the conserved Gag KK10 (residues 263 to
272) and polymerase (Pol) KY9 (residues 901 to 909) epitopes. We studied the im-
pact of the 3 amino acid differences between HLA-B*27:05 and the closely related
HLA-B*27:02 on the HIV-specific CD8 T-cell response hierarchy and on immune
control of HIV. Genetic epidemiological data indicate that both HLA-B*27:02 and
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HLA-B*27:05 are associated with slower disease progression and lower viral loads.
The effect of HLA-B*27:02 appeared to be consistently stronger than that of HLA-
B*27:05. In contrast to HLA-B*27:05, the immunodominant HIV-specific HLA-B*27:02-
restricted CD8 T-cell response is to a Nef epitope (residues 142 to 150 [VW9]), with
Pol KY9 subdominant and Gag KK10 further subdominant. This selection was driven
by structural differences in the F pocket, mediated by a polymorphism between
these two HLA alleles at position 81. Analysis of autologous virus sequences showed
that in HLA-B*27:02-positive subjects, all three of these CD8 T-cell responses im-
pose selection pressure on the virus, whereas in HLA-B*27:05-positive subjects, there
is no Nef VW9-mediated selection pressure. These studies demonstrate that HLA-
B*27:02 mediates protection against HIV disease progression that is at least as
strong as or stronger than that mediated by HLA-B*27:05. In combination with the
protective Gag KK10 and Pol KY9 CD8 T-cell responses that dominate HIV-specific
CD8 T-cell activity in HLA-B*27:05-positive subjects, a Nef VW9-specific response is
additionally present and immunodominant in HLA-B*27:02-positive subjects, medi-
ated through a polymorphism at residue 81 in the F pocket, that contributes to se-
lection pressure against HIV.
IMPORTANCE CD8 T cells play a central role in successful control of HIV infection
and have the potential also to mediate the eradication of viral reservoirs of infec-
tion. The principal means by which protective HLA class I molecules, such as HLA-
B*27:05 and HLA-B*57:01, slow HIV disease progression is believed to be via the par-
ticular HIV-specific CD8 T cell responses restricted by those alleles. We focus here
on HLA-B*27:05, one of the best-characterized protective HLA molecules, and the
closely related HLA-B*27:02, which differs by only 3 amino acids and which has not
been well studied in relation to control of HIV infection. We show that HLA-B*27:02
is also protective against HIV disease progression, but the CD8 T-cell immunodomi-
nance hierarchy of HLA-B*27:02 differs strikingly from that of HLA-B*27:05. These
findings indicate that the immunodominant HLA-B*27:02-restricted Nef response
adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV
CD8 T-cell activity in HLA-B*27:05-positive subjects.
KEYWORDS CD8 T cell, HIV Gag, HIV Nef, HLA, HLA-B*27, human
immunodeficiency virus
HLA-B*27:05 is strongly associated with slow progression in human immunodefi-ciency virus (HIV) infection (1–3). It has been proposed that it is the particular HIV
type 1 (HIV-1)-specific CD8 T-cell responses restricted by HLA-B*27:05 that provide a
likely mechanism for protection. HLA-B*27:05 mediates an immunodominant response
toward an epitope in p24 Gag, KK10 (KRWIILGLNK [residues 263 to 272]). HLA-B*27 has
a unique structure among HLA-B class I molecules in having an absolute requirement
for arginine at position 2 (P2) in the binding peptide (4). Loss of immune control and
progression to AIDS in HIV-infected HLA-B*27:05-positive individuals appeared to be
precipitated by selection of an escape mutation at Gag residue 264, most commonly
R264K or R264G (5–7). This R264X escape mutant is selected prior to, and not as a result
of, the sharp rise in viral load (6). The Arg-264 replacement results in reduced binding
of the epitope to HLA-B*27:05 and reduced recognition of virus-infected cells.
More recently, an HLA-B*27:05-restricted Pol epitope, KY9 (KRKGGIGGY [residues 901
to 909]), has been described (8). The magnitude of responses to this epitope is only
marginally lower than that to KK10 (8). At position 908 (P8) within the KY9 epitope, a
viral escape mutant with an amino acid change from glycine to glutamic acid emerges
soon after the R264X mutation in the Gag KK10 epitope. This would imply that KK10
and KY9 impose selection pressure on the virus at the same time and highlights KY9 as
a contributing factor to HLA-B*27:05-mediated immune control of HIV.
The most prevalent subtype of HLA-B*27 worldwide is HLA-B*27:05, although many
other natural variants of the molecule have been described to date, from HLA-B*27:01
to -B*27:99 (http://www.ebi.ac.uk/ipd/imgt/hla/align.html). Most of these differences
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have a direct impact on the peptide binding groove and therefore on the nature of the
peptides binding that particular HLA-B*27 subtype. The particular peptides presented
by these subtypes could potentially explain differences in disease susceptibility. HLA-
B*27 has been especially well studied because of its strong association with ankylosing
spondylitis (AS), and it is noteworthy that some HLA-B*27 subtypes are associated with
AS and others are not. For example, HLA-B*27:01, -B*27:02, -B*27:04, -B*27:05, -B*27:07,
and -B*27:08 have been linked with AS, whereas HLA-B*27:06 and -B*27:09 are not
associated with AS (9).
HLA-B*27:02 reportedly is present in 1 to 10% of HLA-B*27-positive subjects in
Northern Europe, 20% in Spain and Portugal, 35 to 50% in Greece, and 55% in Arab
and Jewish populations (9–11). However, in Germany this figure is 14% in a population
where HLA-B*27 prevalence is 10% (12), and in Poland this figure is 26 to 29% in a
population where HLA-B*27 prevalence is 14% (13).
As stated above, there are three amino acid differences between HLA-B*27:05 and
HLA-B*27:02. These 3 amino acids line the F pocket of the peptide binding groove,
therefore influencing the type of residue at the carboxy-terminal anchor position (PC).
HLA-B*27:02 has asparagine at HLA position 77, whereas HLA-B*27:05 uses the nega-
tively charged aspartate. The F pocket of HLA-B*27:02 is therefore lined with residues
conferring a lower overall negative charge than HLA-B*27:05, and for this reason the
peptide binding motif does not include basic residues (Lys or Arg) at PC in HLA-B*27:
02-binding peptides, but these are a feature of many of the peptides binding to
HLA-B*27:05. Additionally, HLA-B*27:05 has isoleucine at position 81, in contrast to
alanine in HLA-B*27:02. Thus, the F pocket in HLA-B*27:02 is potentially slightly larger
and may be able to accommodate amino acids with bulkier side chains. Together, these
differences provided a unique opportunity to investigate the differences in the HIV
epitopes presented by HLA-B*27:05 and HLA-B*27:02 and their respective roles in
immune control of HIV.
RESULTS
HLA-B*27:02 is associated with protection against HIV disease progression. In
cohorts that have been studied to determine the impact of host genetic factors on HIV
disease outcome, the prevalence of HLA-B*27:02 is relatively low, approximately 10-fold
lower than that of HLA-B*27:05. Survival analyses were performed on seroconverter
cohorts, and for all four outcomes studied, HLA-B*27:02 associated more strongly with
slower progression than did HLA-B*27:05, though the sample sizes are very limited in
the HLA-B*27:02 group (Table 1; Fig. 1). Both HLA-B*27:02 and HLA-B*27:05 were
associated significantly with mean viral loads lower than those without these alleles,
and there was no significant difference between the two alleles on viral control.
Although, unexpectedly, in the current analyses HLA-B*27:05 was not significantly
associated with slow disease progression, HLA-B*27:05 has been consistently and in
many studies associated with control of HIV viremia, as well as with slow disease
progression (1–3, 5). Our subtype-specific analyses, of both viral setpoint and disease
progression, suggest slightly better protection in both cases conferred by HLA-B*27:02
than HLA-B*27:05. However, in a previous study of viral setpoint only, involving 2,767
subjects, also of European descent, suggested that HLA-B*27:05 (odds of being an
immune controller versus progressor, 3.34) was slightly more protective than HLA-
B*27:02 (odds ratio, 2.53) (2). Thus, these data together would indicate that HLA-B*27:02
is associated with protection against HIV disease progression and provides a degree
of protection similar to or possibly even a somewhat greater than that provided by
HLA-B*27:05.
Nef VW9 is the immunodominant HLA-B*27:02-restricted CD8 T-cell epitope.
To characterize the HIV-specific CD8 T-cell responses associated with HLA-B*27:02 and
immune control of HIV infection, we tested in gamma interfereon (IFN-) enzyme-
linked immunosorbent spot (ELISpot) assays recognition of a panel of 410 overlapping
peptides spanning the B clade proteome (14). The immunodominant response among
7 HLA-B*27:02-positive subjects whose HIV-specific CD8 T-cell responses were ana-
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lyzed was to an epitope in Nef, defined using peptide-major histocompatibility complex
(MHC) tetramers as the 9-mer VRYPLTFGW (Nef residues 133 to 141), confirmed via
tetramer staining (Fig. 2). Summarizing the HLA-B*27-restricted CD8 T-cell responses
observed in these 7 HLA-B*27:02-positive subjects and in 19 HLA-B*27:05-positive
subjects (Fig. 3A) confirms the reversal of the immunodominance pattern observed in
HLA-B*27:05-positive subjects, in which Gag KK10 is dominant and the Pol KY9 re-
sponse codominant or subdominant, and typically there is no HLA-B*27:05-restricted
Nef-specific response. In the HLA-B*27:02-positive subjects, the Nef VW9 response was
dominant, Pol KY9 subdominant, and Gag KK10 below Pol KY9 in the hierarchy (Fig. 3).
HLA-B*27:05 and HLA-B*27:02 have distinct peptide binding preferences. To
help explain the differences observed in the CD8 T-cell immunodominance patterns
observed between HLA-B*27:02-positive and HLA-B*27:05-positive subjects, the
peptide-MHC binding avidity was determined for each of the HLA-B*27-restricted
epitopes. Consistent with the differences in peptide binding motifs between HLA-
TABLE 1 Protective effect of HLA-B*27:02a
aThe top portion presents data from the Multicenter AIDS Cohort Study (MACS) showing comparisons between HLA-B*27-negative subjects (referred to as “others”)
and HLA-B*27:02-positive subjects and HLA-B*27:05-positive subjects for time to CD4 count of 200 mm3, AIDS defined by the CDC 1987 criteria, AIDS defined by
the CDC 1993 criteria, and death. Values for the Cox proportional hazards model are shown. HR, hazard ratio; CI, confidence interval. The bottom portion shows
analysis of variance (ANOVA) for median viral loads (VLs) from the MACS cohort comparing HLA-B*27-negative, HLA-B*27:02-positive, and HLA-B*27:05-positive
subjects.
FIG 1 HLA-B*27:02 is associated with protection against HIV disease progression. HLA differences by log rank test
are shown as follows: fraction of HLA-B*27:02-positive (n  12) and HLA-B*27-negative (n  721) subjects
remaining AIDS free (absolute CD4  200/l) (A) and fraction of HLA-B*27:02-positive (n  13) and HLA-B*27:05-
positive (n  64) subjects remaining AIDS free by the 1987 CDC definition for AIDS.
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B*27:05 (inability to bind Trp and ability to bind basic residues Lys, Arg, and His in the
F pocket) and HLA-B*27:02 (ability to bind Trp and inability to bind basic residues Lys,
Arg, and His in the F pocket), we observed that the Gag KK10 epitope, which is
immunodominant in HLA-B*27:05-positive subjects, bound poorly to HLA-B*27:02;
conversely, the Nef VW9 epitope, which is immunodominant in HLA-B*27:02-positive
subjects, did not bind well to HLA-B*27:05 (Fig. 3C). Overall it is striking that none of the
B*27-restricted peptides tested that had a basic residue, Lys or Arg, at the carboxy-
terminal position (PC) bound successfully to HLA-B*27:02: namely, Gag IK9, Gag KK10,
Gag QK10, Pol FR9, and Env CR9. Also, as has been well described (15, 16), strong
peptide-MHC binding avidity does not necessarily translate into high immunogenicity.
For example, Env HI9 (HRLRDLLLI) binds well to both HLA-B*27:02 and HLA-B*27:05, but
responses were detected only in subjects expressing HLA-B*27:02. Thus, adequate
binding is a requirement for immunogenicity but is not sufficient to predict it.
Structural modeling of the impact of HLA-B*27:05/HLA-B*27:02 polymor-
phisms on F-pocket amino acid compatibility. The crystal structure of HLA-B*27:05 in
complex with the KK10 peptide has been previously determined, but the crystal
structure of HLA-B*27:02 has not been elucidated. Thus, the polymorphisms in the F
pocket that distinguish HLA-B*27:05 from HLA-B*27:02 (17, 18) (D77N, T80I, and L81A)
were modeled to explore the distinct C-terminal peptide (PC) residue preferences
between the two HLA alleles (Fig. 4). KK10 epitope PC residue Lys-10 forms a “peg-in-
hole”-type interaction in the HLA-B*27:05-KK10 structure, forming a stabilizing van der
FIG 2 Characterization of HLA-B*27:02-restricted cytotoxic T-lymphocyte (CTL) responses. (A) IFN- ELISpot assay recognition of a
panel of 410 overlapping peptides spanning the B clade proteome. The amino acid sequences of overlapping peptide and confirmed
optimal epitope and HLA restriction are shown. Gag KK10 is KRWIILGLNLK, Pol KY9 is KRKGGIGGY, and Nef VW9 is VRYPLTFGW. (B)
Confirmative fluorescence-activated cell sorter (FACS) staining of a HLA-B*27:02-positive subject R120 with an HLA-mismatched
tetramer on the left and the HLA-B*27:02-restricted VRYPLTFGW (VW9) on the right.
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Waals interaction with HLA residue Leu-81. This interaction is likely disrupted in
HLA-B*27:02 because of the smaller side chain at residue 81 (Ala in HLA-B*27:02 in
contrast to Leu in HLA-B*27:05) (Fig. 4A). This polymorphism also results in the
widening of the F pocket in HLA-B*27:02, which would tend to increase mobility of the
Lys-10 side chain that could destabilize the peptide.
Additionally, HLA-B*27:05 possesses Asp at position 77, which provides a negative
charge that is favorable for the binding of positively charged basic amino acids. In
contrast, HLA-B*27:02 possesses Asn at position 77, which is neutral and less favorable
for binding to basic amino acids. Although the structural modeling did not reveal an
obvious difference in the abilities of Asp-77 and Asn-77 to form a hydrogen bond with
the main chain N group of Lys-10 in the KK10 peptide, this difference in charge could
also play a role in the differential selection of amino acids based on their C-terminal
residues between HLA-B*27:05 and HLA-B*27:02. Together, these observations are
consistent with the low avidity of KK10 peptide-MHC binding to HLA-B*27:02 (Fig. 3C)
FIG 3 Differential recognition of HLA-B*27-restricted epitopes. (A) Epitope responses from one representative HLA-B*27:05-positive subject (top) and one
HLA-B*27:02-positive subject (bottom). CD8 is shown on the x axis and tetramer-PE on the y axis. (B) (Left) Percentage of HLA-B*2702-positive subjects (n 
7) and HLA-B*2705-positive subjects (n  19) making responses to the indicated epitopes. **, P  0.001, Fisher’s exact test. (Right) Differential recognition of
HLA-B*27 epitopes is related to peptide-MHC binding avidity. Peptide-MHC binding avidity is measured as the Kd (equilibrium dissociation constant) and shown
as log10 (1/Ka), where Ka is the equilibrium constant for dissociation of an acid. Shaded are the three epitopes Gag KK10 (KRWIILGLNLK), Pol KY9 (KRKGGIGGY),
and Nef VW9 (VRYPLTFGW).
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and our observation that KK10 is not the dominant HIV epitope in HLA-B*27:02-positive
individuals (Fig. 3B).
We next modeled the interaction between HLA-B*27:05 and HLA-B*27:02 with Trp as
the C-terminal peptide residue. The tighter F pocket in HLA-B*27:05 is unlikely to
accommodate KK10 peptide PC 10-Trp because of a potential steric clash with HLA
residue Leu-81. In contrast, the wider F pocket in HLA-B*27:02 is ideally suited to bind
Trp, which could form van der Waals contacts with Ala-81 (Fig. 4B). These observations
are consistent with the switch in immunodominant responses from KK10 in HLA-
B*27:05 individuals to VW9 in HLA-B*27:02 individuals and demonstrate the extreme
peptide selectivity of HLA alleles that differ at only a few key residues in the peptide
binding groove.
Immune escape selection pressure matches CD8 T-cell immunodominance
hierarchy. A hallmark of disease progression in subjects expressing HLA-B*27:05 is the
impact of escape within Gag KK10 as a precipitant. To date, progression to AIDS
(CD4  200) has not been observed in an HLA-B*27:05-positive subject without escape
occurring in this epitope. However, the kinetics of viral escape are strongly influenced
by the immunodominance hierarchy of the CD8 T-cell responses (19). Analysis of
autologous viral sequences in HLA-typed subjects demonstrated that in HLA-B*27:05-
positive subjects, the strongest selection pressure is imposed by the dominant Gag
KK10 response, followed closely by the codominant or subdominant Pol KY9 response,
and as expected, no selection pressure was evident within the Nef VW9 epitope (Table
2; odds ratios for escape in HLA-B*27:05-positive versus HLA-B*27-negative subjects at
R264X [Gag] and K903X [Pol] were 15 and 10, respectively). In contrast, strong immune
selection pressure on the Nef VW9 and Pol KY9 epitopes was observed in HLA-B*27:
02-positive subjects, and although escape mutation at R264X was observed in a
minority of HLA-B*27:02-positive subjects (3 of 22 subjects studied), the selection of
escape variants in Gag KK10 was clearly less frequent than in Nef VW9 or Pol KY9 (odds
FIG 4 Structural modeling of the impact of HLA-*27:05/HLA-B*27:02 polymorphisms on F-pocket amino
acid compatibility. The crystal structure of HLA-B*27:05 in complex with the KK10 peptide (17, 18) was used
to model how the polymorphisms in HLA-B*2702 might impact C-terminal anchoring of peptide epitopes.
Wincoot was used to generate a model with the following mutations in the HLA-B*27:05 F pocket: D77N,
T81I, and L81A. The peptide was modeled with a Trp or a Lys at position 10. (A) The KK10 peptide is shown
in red, with Lys-10 depicted by red sticks. Left images show the HLA-HLA-B*2705 F pocket in gray, with
Asp-77, Thr-80, and Leu-81 depicted by gray sticks. The dotted line represents a van der Waals contact
between Lys-10 and Leu-81. Right images show the modeled HLA-B*2702 F pocket in cyan, with Asn-77,
Ile-80, and Ala-81 depicted by cyan sticks. A red cross represents the loss of interactions between Lys-10
and Ala-81 in HLA-B*27:02. (B) KK10 peptide modeled with Trp at position 10 is shown in blue, with Trp-10
depicted by blue sticks. Left panels show the HLA-B*2705 F pocket in gray, with Asp-77, Thr-80, and Leu-81
depicted by gray sticks. A red circle shows the steric clash that would occur between Trp-10 and Leu-81.
Right images show the modeled HLA-B*2702 F pocket in cyan, with Asn-77, Ile-80, and Ala-81 depicted by
cyan sticks. Black dotted lines represent a van der Waals contact, and red dotted lines represent hydrogen
bonds.
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ratios for escape in HLA-B*27:02-positive versus HLA-B*27-negative subjects at R264X
[Gag], R902X [Pol], and L137X [Nef] were 4, 15, and 15, respectively). Consistent with
previous studies comparing the footprints of closely related HLA types on the same
epitope (20, 21) we observed in Pol KY9 different footprints for HLA-B*27:02 (dominant
footprint, R902X) and HLA-B*27:05 (dominant footprint, K903X).
DISCUSSION
These studies focus on HLA-B*27 and the mechanisms by which this molecule is
associated with protection in HIV infection. We show that HLA-B*27:02 expression is
associated with slower progression to HIV disease and also with lower viral loads than
in the absence of expression of HLA-B*27. HLA-B*27:02 appears to be at least as
TABLE 2 Analysis of selection pressure imposed by HLA-B*27:05- and HLA-B*27:02 positivity on immunodominant viral epitopesa
aSelection pressure on Gag KK10 (residues 263 to 272), Pol KY9 (residues 901 to 909), and Nef VW9 (residues 133 to 141) epitopes was examined in HLA-B*27:05-
positive (n  21), HLA-B*27:02-positive (n  22), and HLA-B*27-negative (n  458) subjects. P values were obtained from Fisher’s exact test.
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protective as, and may be slightly more protective than, HLA-B*27:05. The immuno-
dominant HLA-B*27:02-restricted HIV-specific CD8 T-cell response is directed toward
an epitope in Nef (VRYPLTFGW [residues 133 to 141]) that is not HLA-B*27:05 restricted.
The two principal HLA-B*27:05-restricted epitopes, Gag KK10 and Pol KY9, are both also
HLA-B*27:02 restricted, but Gag KK10 is the subdominant HLA-B*27:02-restricted re-
sponse. These distinct HIV-specific CD8 T-cell hierarchies are confirmed in the studies
showing the selection of escape mutants within these epitopes. The strongest selection
pressure in the HLA-B*27:02-positive subjects is for escape within Nef VW9 and Pol KY9,
with weak pressure evident for escape within Gag KK10. These data suggest that while
the immunodominant Gag KK10 response may play an important part in HLA-B*27:05-
mediated immune control of HIV, access to the Nef VW9 epitope and alteration of the
CD8 T-cell immunodominance hierarchy in subjects expressing HLA-B*27:02 do not
reduce HLA-B*27-associated protection against HIV disease progression.
As described above, the prevailing hypothesis is that HLA-B*27 is protective against
HIV disease progression because the immunodominant response, Gag KK10, is highly
efficacious, killing virus-infected target cells very soon after viral entry (8), and escape
mutants are typically selected late in the course of infection (5) because of the crippling
impact of the R264K or R264G mutation in the absence of a simultaneous compensa-
tory mutation at S173T or E260D, respectively (22, 23). This hypothesis has been
extended to explain HLA-B*57-mediated control also, a broad Gag-specific response
(24) here being even more protective than that generated in HLA-B*27-positive sub-
jects and multiple mutations required in several Gag epitopes, each likely to occur at
a detriment to viral fitness (25, 26).
Although there are exceptions—HLA-B*14:02 and HLA-B*51:01 being two of these
(27, 28)—most of the HLA-B alleles that have shown a well-documented association
with favorable control of viremia, including HLA-B*27:05, HLA-B*57, HLA-B*58:01, HLA-
B*13:02, HLA-B*52:01, and HLA-B*81:01 (29–32), have an immunodominant anti-HIV
CD8 T-cell response within p24 Gag. In general, HLA molecules associated with more
rapid progression to AIDS, such as HLA-B*18:01, HLA-B*35:01, and HLA-B*58:02, show
dominant responses directed at non-Gag epitopes such as Nef or Env (16, 24, 33–35).
Here we show that the HLA-B*27:02 is at least as protective as HLA-B*27:05, and the
immunodominant HIV-specific epitope is located in Nef. Although Nef targeting may
not generally be associated with improved control of HIV (24, 36, 37), a study of simian
immunodeficiency virus (SIV) infection in Mamu-B*08 rhesus macaques, an animal
model for HLA-B*27-mediated elite control (38), showed that the frequency of the
CD8 T-cell response against a Nef epitope correlated significantly with reduced
acute-phase viremia (39). This is one of the first models to demonstrate that a
vaccine-induced Nef-specific CD8 T-cell response can control replication of an AIDS
virus in an animal model of MHC class I-associated control. Indeed, elite control of SIV
in macaques expressing one of the protective MHC alleles, Mamu-B*08 and Mamu-
B*17, have little or nothing in the way of Gag responses. Protective responses appear
to lie exclusively in Nef or Vif. Indeed, it is striking that the immunodominant Mamu-
B*17 epitope in Nef, IRYPKTFGW (40), corresponds exactly with the immunodominant
HLA-B*27:02-restricted epitope described here, VRYPLTFGW. Mamu-B*17 in fact bears
strong similarity with HLA-B*27:02 in binding peptides that carry Arg at P2 and Trp at
PC (41). It seems remarkable and not coincidental that two MHC class I molecules that
have evolved independently but, by convergent evolution (42), possess the ability to
bind similar peptides can mediate, independently, control of SIV and HIV infection,
respectively.
Thus, although immunodominant p24 Gag-specific immune responses are generally
associated with effective immune control of HIV and Nef-specific CD8 T-cell responses
are not, this does not exclude the fact that certain non-Gag-specific CD8 T-cell
responses may also contribute to successful suppression of viral replication. Further-
more, as evidenced by the finding of escape mutations within Gag KK10, albeit in a
minority if HLA-B*27:02-positive subjects, the Gag KK10-specific response may continue
to contribute to control of HIV in HLA-B*27:02-positive subjects, even if it is not the
HLA-B*27:02-Mediated Control of HIV-1 Journal of Virology
February 2018 Volume 92 Issue 4 e01685-17 jvi.asm.org 9
dominant response. Numerous previous examples of subdominant responses being
more efficacious in control of virus infections, including HIV, have been presented (43).
The reasons for the differences observed between HLA-B*27:05 and HLA-B*27:02 in
the CD8 T-cell immunodominance hierarchy were explored using structural modeling.
These analyses demonstrated a clear structural difference within the F pockets of the
two alleles, mainly attributed to the L81A polymorphism. The narrower F pocket in
HLA-B*27:05 (governed by Leu-81), although ideally suited for binding to peptides with
Lys at the C terminus, would likely be unable to accommodate the larger Trp side chain
in the Nef VW9 peptide. On the other hand, the wider F pocket in HLA-B*27:02
(governed by Ala-81) would likely form a less stable interaction with Lys-10 but is ideally
suited for interactions with peptides with Trp at the C terminus. The resulting low
binding avidity of HLA-B*27:02 for Gag KK10 and high binding avidity for Nef VW9, and
the converse for HLA-B*27:05, largely explain the altered immunodominance patterns
and consequent escape hierarchies (19, 44) observed.
Comparisons between the CD8 T-cell responses restricted by HLA-B*27:02 and
HLA-B*27:05 have not been made previously in HIV infection, but a similar study has
been undertaken with regard to hepatitis C virus (HCV) infection (45). As in HIV,
HLA-B*27 is associated with improved HCV disease outcome (46, 47), and also as in HIV,
HLA-B*27:02 appears to present more epitopes than HLA-B*27:05. Of three HLA-B*27-
restricted HCV NS5B-specific epitopes, two are presented by both HLA-B*27:02 and
HLA-B*27:05 (NS5B amino acid sequences ARMILMTHF and GRAAICGKY) and a third by
HLA-B*27:02 only (amino acid sequence ARHTPVNSW). It is striking that the HLA-B*27:
02-restricted epitope ARHTPVNSW carries Trp at PC, just as the Nef VW9 HLA-B*27:02-
restricted epitope described here, which from the structural considerations described
above would not be expected to be accommodated within the smaller F pocket of
HLA-B*27:05. Also, it is notable that these HLA-B*27:02-specific epitopes, ARHTPVNSW
and Nef VW9, in HCV and HIV, respectively, are both clearly the immunodominant
responses among HLA-B*27:02-positive individuals. This is consistent with findings from
comparisons of HLA-B*44:02 and HLA-B*44:03 (48), HLA molecules differing by only a
single amino acid residue, demonstrating that the greater capacity within the HLA-
B*44:03 peptide-binding groove allows a larger repertoire of peptides to bind. Also,
structural studies of peptide binding to HLA-B*57:03 (18), which, like HLA-B*27:02, has
Ala at position 81, show that large residues, such as Trp, binding in the appropriately
sized F pocket make greatly increased numbers of interatomic van der Waals contacts
that contribute to the stability of the peptide-MHC complex and therefore to immu-
nodominance of the response.
The limitations of the current study include the fact that HIV-infected HLA-B*27:02-
positive subjects were very hard to find and therefore only a relatively small number
were studied. In addition, other than defining the specificity of the HIV-specific CD8
T-cell responses and the seeking selection pressure on the virus through the three main
specificities of interest, sample availability limited further analyses to investigate the
ability of the HLA-B*27:02 Nef response to inhibit viral replication. In addition, the study
has focused solely on the HLA-B*27-restricted CD8 T-cell response, although it is
known that HLA-mediated effects on HIV disease outcome may arise via other mech-
anisms (49–51). In particular, the finding that Bw4-80I-expressing alleles in combination
with high-expression KIR3DL1 alleles are associated with more effective control of HIV
(49) provides an additional potential explanation for the improved action of HLA-
B*27:02 (a Bw4-80I allele) in comparison with HLA-B*27:05 (a HLA-Bw4-80T allele) in
control of HIV.
In conclusion, despite the subdominance of Gag KK10 in HLA-B*27:02-positive
subjects, HLA-associated protection against HIV disease progression is at least as strong
as that mediated by HLA-B*27:05. The immunodominant Nef VW9-specific response
may contribute to this additional immune control, in combination with contributions
made via the Gag KK10 and Pol KY9 specificities that are shared with HLA-B*27:05. In
addition, there may be additional mechanisms, such as the HLA-B*27:02 interaction
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with KIR3DL1, operating to supplement further the antiviral immune effects of HLA-
B*27:02 against HIV.
MATERIALS AND METHODS
Study cohorts. We studied treatment-naive subjects with chronic HIV-1 infection from (i) Warsaw,
Poland, (ii) Athens, Greece, (iii) Mexico City, Mexico, (iv) Bonn, Germany, (v) Boston, MA, (vi) Barcelona,
Spain, and (vii) Thames Valley, UK. Several cohorts were used for the study because of the paucity of
HIV-infected subjects expressing HLA-B*27:02. Subjects were included in the study if they were HIV
infected and HLA-B*27:02 positive and samples were available for either ELISpot assays or viral sequenc-
ing. The absolute CD4 count of these study subjects was 460 cells/l (interquartile range [IQR], 287 to
647), and the median viral load was 11,399 copies/ml of plasma (IQR, 437 to 29,592). Study subjects from
all cohorts gave written informed consent for their participation. The study was approved by the
institutional review boards of the University of Oxford, University of Warsaw, Medical School, National
and Kapodistrian University of Athens, University of Bonn, National Institute of Respiratory Diseases in
Mexico City, Ragon Institute, and University Hospital Germans Trias i Pujol in Badalona (Barcelona, Spain).
For survival analyses, we included 783 individuals from five studies—AIDS Linked to the Intravenous
Experience (ALIVE; n  12) (52), the Multicenter AIDS Cohort Study (MACS; n  417) (53), the Multicenter
Haemophilia Cohort Study (MHCS; n  243) (54), the San Francisco City Clinic Cohort (SFCCC; n  74)
(55), and the DC Gay Cohort Study (DCGCS; n  37) (56)—with prospective follow-up and known dates
of seroconversion. For HIV mean viral load analyses, we included 3,280 individuals enrolled in one of five
prospective studies: the Multicenter AIDS Cohort Study (n  1,583), the Military HIV Research Program
(MHRP; n  191), the Ragon Institute of MGH, MIT and Harvard HIV Controller study (n  975), the Study
of the Consequences of the Protease Inhibitor Era (SCOPE; n  386), and the Swiss HIV Cohort study
(n  145). There was an overlap of 414 subjects between the two analyses.
Measures of disease outcome in the survival analyses of HIV-infected subjects were an absolute CD4
count of 200 cells/mm3, meeting the 1987 CDC definition of AIDS (AIDS defining illness), meeting the
1993 CDC definition of AIDS (AIDS defining illness) or decline to absolute CD4 count of 200 cells/mm3,
and death.
The frequency of amino acid polymorphisms among HLA-B*27-negative, B-clade-infected individuals
within the Gag, Pol, and Nef HLA-B*27 epitopes shown in Table 2 was determined from analysis of 555
AIDS Clinical Trials Group and 245 Western Australia HIV Cohort Study subjects (57).
HLA typing. HLA genotyping was performed by either PCR–sequence-specific oligonucleotide
probing (PCR-SSOP), PCR–sequence-based typing (PCR-SBT) using the Sanger sequencing technology
recommended by the 13th International Histocompatibility Workshop (http://www.ihwg.org), or next-
generation sequencing using the Roche 454 platform (58).
Amplification and sequencing of HIV genes by PCR. Gag, Pol, and Nef sequences were generated
from either viral RNA or genomic DNA. DNA was extracted from whole blood, and viral RNA was
extracted from plasma using an RNA extraction minikit (Qiagen UK) in accordance with the manufac-
turer’s instructions. Reverse transcription of RNA to cDNA was undertaken using a Superscript III one-step
reverse transcriptase kit (Invitrogen) as a one-step reaction combined with outer PCR according to the
manufacturer’s instructions and amplified by nested PCR to obtain population sequences. Sequencing
was undertaken using the BigDye Ready Reaction Terminator Mix (V3) (Applied Biosystems UK) analyzed
using Sequencher v4.8 (Gene Codes Corporation) and manually aligned using Se_Al software.
IFN- ELISpot assays.We tested ex vivo peripheral blood mononuclear cells (PBMCs) against a panel
of 410 overlapping peptides (OLPs) spanning the entire HIV-1 proteome to screen for IFN- ELISpot
responses (14). We additionally tested putative optimal epitopes by ELISpot assay using ex vivo PBMCs
from HLA-B*27:02- and HLA-B*27:05-positive subjects.
Cell staining and flow cytometry. Cell staining from cryopreserved PBMCs was undertaken using
anti-CD3-Pacific orange (Invitrogen), anti-CD8-Alexa Fluor 700 (BD Biosciences), and HLA-B*27 tetramers
conjugated to phycoerythrin (PE). Dead cells were gated out using a LIVE/DEAD viability kit (Invitrogen).
Peptide–MHC-I binding assay. Peptide affinity to HLA class I molecules was determined using a
luminescent oxygen channeling immunoassay (LOCI) (59). Briefly, peptides were dissolved in phosphate-
buffered saline (PBS)–0.1% Lutrol F68 by sonication for 10 min. Peptides were titrated in 384-well
microplates using a Microlab STAR liquid handling robot (Hamilton Robotics). Recombinant, denatured
HLA-C heavy chain (HC) was diluted into PBS–0.1% Lutrol F68/100 mM Tris/maleate (pH 6.6) containing
prefolded, recombinant beta-2 microglobulin (2m) on ice. The HC-2m mix was added 1:1 to the
peptide titrations and incubated for 48 h at 18°C to allow peptide–MHC-I complex folding. After complex
folding, samples were transferred to 384-well Optiplates and streptavidin-coated donor beads (PerkinEl-
mer; 6760002) and W6/32-conjugated acceptor beads (PerkinElmer; 6762001; in-house conjugated with
W6/32) diluted in PBS–0.1% Lutrol F68 were added to a final concentration of 5 g/ml each. The
Optiplates were incubated overnight and luminescence was measured in an EnVision 2103 multilabel
reader.
Structural analysis. The HLA-B*27:05 KK10 structure (PDB code 4G9D) (17) was used to model
analyze C-terminal peptide residue interaction with the F pocket, in which Lys-10 was mutated to Trp-10.
This structure was also used to model the F pocket of HLA-B*27:02 (D77N, T81I, and L81A) with both
Lys-10 and Trp-10. Sequences were adjusted with COOT (60), and graphical representations were
prepared with PYMOL (PyMOL molecular graphics system, version 1.8; Schrodinger, LLC).
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